Glenmark Of India Seeks Government Probe Into Trial Manipulator
This article was originally published in PharmAsia News
India's Glenmark Pharmaceuticals accused a government hospital participating in a trial of one of its drug trials of manipulating data and engaging in unfair practices, causing a halt of the trial. Glenmark filed a complaint with the Drug Controller General of India asking for an immediate audit of the hospital. At issue is Glenmark's Oglemilast asthma drug based on a PDE4 inhibitor molecule. The complaint also questioned whether the screening of volunteers was done properly. (Click here for more
You may also be interested in...
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Ai Biomed’s PTeye helps to identify parathyroid tissue during thyroid surgery. Medtronic ENT also announced the FDA clearance of its NIM Vital electromyographic system for nerve monitoring during surgery.